ABSTRACT
AIM: To investigate the link between cell stiffness and volume-regulated anion current (VRAC) in aortic endothelium. METHOD: Bovine aortic endothelial cells (BAECs) were exposed to methyl-beta-cyclodextrin (MbetaCD) to deplete cellular cholesterol and the changes in cellular stiffness were measured by micropipette aspiration. VRAC density was measured electrophysiologically in the same cell populations. Furthermore, to probe the effects of cholesterol depletion on the mechanics of 'deep' cytoskeleton, we employ a novel technique to analyse correlated motion of intracellular particles. RESULTS: We show that cholesterol depletion results in cellular stiffening and an upregulation of VRAC density. Replenishing cellular sterol pool with epicholesterol, a chiral analogue of cholesterol, abrogates both of these effects. This indicates that cholesterol sensitivity of both cell mechanics and VRAC are due to changes in the physical properties of the membrane rather than due to specific sterol-protein interactions. We also show that cholesterol depletion increases the stiffness of the 'deep cytoskeleton' and that disruption of actin filaments abolishes both cell stiffening and upregulation of VRAC due to cholesterol depletion. Furthermore, comparing BAECs to human aortic endothelial cells (HAECs), we show that BAECs that are inherently stiffer also develop larger VRACs. CONCLUSIONS: Taken together, our observations suggest an increase in the cytoskeleton stiffness has a facilitatory effect on VRAC development. We suggest that stiffening of the cytoskeleton increases tension in the membrane-cytoskeleton layer and that in turn facilitates VRAC.
Subject(s)
Cytoskeleton/physiology , Endothelial Cells/physiology , Endothelium, Vascular/physiology , Ion Channels/metabolism , Animals , Anticholesteremic Agents , Aorta , Cattle , Cell Membrane/physiology , Cell Size , Cells, Cultured , Cholesterol/analysis , Cholesterol/metabolism , Cytoskeleton/metabolism , Elasticity , Electrophysiology , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/metabolism , Humans , Lipid Bilayers , Micromanipulation , beta-Cyclodextrins/pharmacologyABSTRACT
Biological transport of moderately permeant compounds is obscured by diffusion of the compounds back across the membrane, so characterization of the transport of such compounds requires correction for permeability. A relatively simple method for determining kinetic parameters for moderately permeant compounds is presented here. After evaluating a compound's apparent permeability coefficient, its steady-state uptake is measured as a function of concentration. By comparing the concentration dependence of uptake measured both in the presence and in the absence of a complete inhibitor of the transporter, K(m) and Vmax for transport of that substrate may be calculated. When used to analyze transport of tyramine and hydroxyephedrine by the vesicular amine transporter, this method yields results consistent with other methods and with values for analogous impermeant substrates. In bovine adrenal chromaffin vesicles, tyramine and (-)erythro-hydroxyephedrine have apparent permeability coefficients of 4.7 +/- 1.0 x 10(-9) and 1.1 +/- 0.4 x 10(-8) cm/s, respectively. Values for K(m) are 15 +/- 9 and 34 +/- 14 microM and for Vmax are 1.3 +/- 0.2 and 1.4 +/- 0.9 nmol/min.mg of membrane protein, respectively.
